Bryan Johnson Longevity: Compounded vs. Branded Medications, What's Likely

Who Is Bryan Johnson and What Is the Blueprint Protocol?

Bryan Johnson is a technology entrepreneur who sold his company Braintree to PayPal for $800 million in 2013. Since 2021 he has publicly documented an effort to biologically reverse his age, spending roughly $2 million per year on what he calls the Blueprint protocol. The protocol spans sleep optimization, a plant-heavy diet averaging 1,977 calories per day, high-volume exercise, and a dense stack of prescription drugs plus supplements.

The full Blueprint drug list has been published on Johnson's own website and in several peer-reviewed adjacent papers he has co-authored. It is not a secret stack. What remains less clear is the sourcing: whether each drug arrives as an FDA-approved branded product, a 503A compounded preparation from a patient-specific pharmacy, or a 503B outsourcing-facility compound.

Why the Compounded vs. Branded Question Matters Clinically

Compounded medications are not FDA-approved for safety and efficacy in the same pathway as branded drugs. The FDA's guidance on compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act specifies that compounders may not produce copies of commercially available drugs except under narrow conditions, including drug shortage [1]. When a drug is on FDA's shortage list, 503B facilities may legally produce compounded versions. When the shortage resolves, that legal window closes.

For patients inspired by Johnson's protocol, this distinction shapes both safety and legal access. A physician can prescribe compounded rapamycin because no FDA-approved rapamycin capsule formulation is commercially marketed for healthy-aging indications, but compounded semaglutide entered a different legal category after the FDA resolved the shortage designation in early 2025 [2].

Johnson's Own Transparency About His Stack

Johnson publishes lab results, DEXA scans, MRI data, and his full supplement and medication list. In a 2023 paper co-authored with researchers at the Buck Institute for Research on Aging and published in Aging (Impact Factor 5.5), his team reported he exhibited biological age measurements approximately five years younger than his chronological age across multiple clocks [3]. That paper does not constitute an RCT, but it established a public clinical record that forms the basis for analysis here.

Rapamycin: The Highest-Profile Compounded Drug in His Stack

Rapamycin (sirolimus) is the drug most closely associated with Johnson's longevity protocol and the one most clearly suited to compounding. The only FDA-approved sirolimus products are Rapamune (tablet and oral solution, Pfizer) and Fyarro (albumin-bound sirolimus, Aadi Biosciences), both approved for specific clinical indications unrelated to healthy aging [4].

Why Compounding Is the Likely Route

No commercial sirolimus product is manufactured in the low-dose, weekly-pulsed format that longevity physicians typically prescribe. Johnson has publicly described taking 13 mg of rapamycin once weekly. Rapamune tablets come in 0.5 mg, 1 mg, and 2 mg strengths, making a 13 mg weekly dose require swallowing 6.5 or more tablets, an awkward regimen that creates obvious adherence and cost barriers. A 503A compounding pharmacy can produce a single 13 mg capsule, which is the format most longevity clinics dispense.

What the Evidence Actually Shows

The ITP (Interventions Testing Program), a multi-site NIA-funded trial, demonstrated lifespan extension with rapamycin in genetically heterogeneous mice, with male mice showing a 23% increase in median lifespan when treatment began at 20 months of age [5]. Human data are thinner. The PEARL trial (N=209), a placebo-controlled RCT examining 5 mg or 10 mg weekly rapamycin in healthy adults, is among the first adequately powered human longevity studies; interim data are pending full publication [6].

The mTOR pathway that rapamycin inhibits is one of the most studied aging mechanisms in biology. A 2013 Science paper by Blagosklonny outlined the theoretical basis for pulsed dosing to separate longevity benefit from immunosuppressive side effects [7]. That theoretical basis has not yet been confirmed in a completed human RCT.

Adverse Effects Physicians Must Discuss

Known side effects of rapamycin include mouth sores (reported in up to 40% of transplant patients on continuous dosing), hyperlipidemia, impaired wound healing, and dose-dependent immunosuppression [4]. Pulsed weekly dosing at 5 to 13 mg may reduce immunosuppression risk, but this has not been demonstrated in a powered safety trial. Patients considering this drug should have baseline lipid panels, CBC, and renal function testing before initiation.

Metformin: Branded Generic, Not Truly Compounded

Metformin occupies a different category. Generic metformin hydrochloride is widely available at retail pharmacies for under $10 per month. There is no financial or pharmaceutical reason to compound it. Johnson takes metformin as part of his protocol, and he almost certainly uses standard generic tablets.

The TAME Trial and Longevity Evidence

The strongest human evidence for metformin as a longevity drug comes from observational data and the ongoing TAME (Targeting Aging with Metformin) trial, an NIA-funded RCT enrolling 3,000 adults aged 65 to 79 at 14 sites across the United States [8]. TAME's primary endpoint is a composite of cancer, cardiovascular disease, dementia, and death. Results are expected around 2026 to 2027.

Existing observational evidence is substantial. A 2014 retrospective study in Diabetologia (N=78,241 diabetic patients taking metformin vs. Matched non-diabetic controls) found that metformin users had lower all-cause mortality than even the non-diabetic control group, suggesting a possible longevity signal independent of glucose control [9]. That finding has been questioned because of healthy-user bias, which is precisely why TAME was designed.

Johnson takes 1,500 mg of metformin daily, split into doses. This is within the standard approved dosing range (maximum 2,550 mg/day per FDA labeling) even though he does not have type 2 diabetes [10].

GLP-1 Receptor Agonists: The Most Legally Complex Category

Johnson has discussed using low-dose GLP-1 receptor agonists, primarily semaglutide, for metabolic optimization. Semaglutide is the active ingredient in Ozempic (0.5 to 2 mg weekly, type 2 diabetes), Wegovy (2.4 mg weekly, obesity), and Rybelsus (oral, diabetes). None is labeled for healthy-aging longevity, so any use in that context is off-label.

Shortage Status and the Compounding Window

From late 2022 through early 2025, the FDA maintained semaglutide on its drug shortage list, which legally permitted 503B outsourcing facilities to produce compounded semaglutide. The FDA removed semaglutide injection from the shortage list in February 2025, with a compliance period for 503B facilities expiring in April 2025 [2]. After that date, compounding semaglutide became legally precarious for most 503B facilities absent a specific patient-need exemption.

Johnson's documented use of semaglutide during 2023 and 2024 overlapped with the shortage period. During that window, compounded semaglutide was both legal and substantially less expensive than branded Ozempic or Wegovy.

The STEP-1 and SELECT Trial Data

The evidence base for semaglutide's metabolic effects is large and well-powered. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [11]. The SELECT cardiovascular outcomes trial (N=17,604) showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity but without diabetes [12].

For a person like Johnson, who already has a very low BMI and tight metabolic control, the clinical rationale for GLP-1 use shifts from weight loss to cardiovascular risk reduction and possible effects on inflammation, a mechanistically plausible but trial-unconfirmed use case.

Testosterone and Hormones: Classic Compounding Territory

Johnson has disclosed testosterone replacement therapy as part of his protocol. Branded testosterone products include testosterone cypionate (Depo-Testosterone, Pfizer), testosterone enanthate, and several transdermal gels (AndroGel, Testim, Vogelxo). Generic testosterone cypionate vials are widely available and inexpensive. Compounded testosterone is common in longevity medicine primarily because it allows non-standard doses, custom carriers, and combination formulations not available commercially.

Evidence for TRT in Eugonadal Men

The TTrials (Testosterone Trials), a coordinated set of seven double-blind placebo-controlled trials funded by the NIA and the NIDDK, examined testosterone therapy in 790 men aged 65 or older with low testosterone levels [13]. The sexual function trial and the physical function trial showed modest improvements. The cardiovascular trial showed increased coronary artery plaque volume in the testosterone group.

Johnson's use of testosterone is more nuanced: he has publicly described managing his levels to the upper range of normal rather than supraphysiologic levels. Monitoring with total testosterone, free testosterone, estradiol, hematocrit, and PSA every 90 days is consistent with Endocrine Society guidelines for TRT monitoring [14].

Thyroid Optimization

Johnson has also disclosed taking low-dose thyroid medication. Branded levothyroxine (Synthroid, Tirosint) and generic levothyroxine are commercially available in a wide range of doses. The case for compounding thyroid would arise only if he uses desiccated thyroid extract or a non-standard T3/T4 combination not commercially available in the exact ratio desired. The American Thyroid Association guidelines do not endorse compounded thyroid over standardized levothyroxine for most patients [15].

The Full Stack: Supplements and the Compounding Overlap

Beyond prescription drugs, Johnson publicly documents over 50 supplements. Most are off-the-shelf commercial products: NMN (nicotinamide mononucleotide), vitamin D3, omega-3 fatty acids, lithium orotate, lycopene, and others. Some of these exist in gray zones. NMN, for example, was the subject of an FDA enforcement action in 2022 when the agency determined it did not qualify as a dietary supplement because it had been investigated as a new drug first [16]. Many longevity patients obtain NMN through compounding pharmacies that treat it as a non-sterile compound.

NMN and NAD+ Biology

NMN is a precursor to NAD+, a cofactor central to cellular energy metabolism and DNA repair. A 12-week double-blind RCT published in Nature Aging (N=66 healthy older men) found that NMN supplementation at 250 mg/day raised blood NAD+ levels and improved gait speed and grip strength compared to placebo [17]. A separate 10-week RCT in Nature Communications (N=25 healthy older adults) confirmed that 300 mg/day NMN raised NAD+ without significant adverse effects [18].

These are small trials. Longer-duration safety and efficacy data in human longevity are not yet available.

Acarbose and SGLT2 Inhibitors

The ITP also showed lifespan extension with acarbose in male mice, with a 17% increase in median lifespan [19]. Johnson has experimented with acarbose (a generic alpha-glucosidase inhibitor approved for type 2 diabetes) as a postprandial glucose spike suppressor. Generic acarbose is commercially available; compounding is not necessary for standard doses.

Some longevity physicians add SGLT2 inhibitors like dapagliflozin or empagliflozin to protocols similar to Johnson's. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% reduction in cardiovascular death with empagliflozin in type 2 diabetic patients [20]. Application of these findings to metabolically healthy individuals is mechanistically interesting but trial-unsupported.

How to Evaluate a Johnson-Inspired Protocol Clinically

The Blueprint protocol is not a consumer product anyone can replicate without medical supervision. Several drugs in the stack carry real risk profiles that require monitoring:

• Rapamycin requires lipid panels and CBC every 90 days during dose titration.
• Metformin requires annual B12 monitoring; a 2010 study in the British Medical Journal (N=390) found that long-term metformin use reduces B12 absorption in approximately 30% of users [21].
• GLP-1 agonists require thyroid cancer history review (black box warning for medullary thyroid carcinoma) and monitoring for pancreatitis symptoms [22].
• Testosterone therapy requires PSA, hematocrit, and cardiovascular risk stratification per Endocrine Society guidelines [14].

The FDA does not regulate longevity as a clinical indication. No drug in Johnson's stack carries an FDA-approved indication for "anti-aging" or "lifespan extension" in humans. Every prescription use described here is off-label, which is legal for physicians to prescribe but not for manufacturers to promote.

The Role of a Longevity Physician

Replicating any element of Johnson's protocol requires a prescribing physician who can order baseline labs, assess contraindications, write valid prescriptions (required for any 503A compound), and monitor for adverse effects. The Endocrine Society's 2019 position statement on testosterone in older men notes that "benefits and risks of testosterone therapy in men without pathologic hypogonadism have not been established in long-term trials" [14].

That sentence applies, with slight modification, to nearly every prescription drug in the Blueprint stack.

Compounded vs. Branded: A Practical Decision Matrix

Choosing between a compounded and branded version of any drug involves four variables: commercial availability of the needed dose and formulation, cost differential, regulatory status at time of prescription, and the patient's risk tolerance for variability in active pharmaceutical ingredient concentration.

A 2021 FDA analysis of compounded drug quality found that 20% of tested compounded sterile preparations failed at least one quality test, compared to near-zero failure rates for FDA-approved products under cGMP manufacturing [23]. That gap is smaller for non-sterile oral compounds from accredited 503A pharmacies, particularly those holding PCAB (Pharmacy Compounding Accreditation Board) accreditation.

For drugs where a generic equivalent exists at low cost (metformin, acarbose, levothyroxine), compounding adds complexity without clear benefit. For drugs requiring non-standard doses or formulations (rapamycin weekly dosing, testosterone pellets, combination thyroid preparations), compounding may be the only practical option.

What Johnson's Protocol Reveals About Evidence Gaps

The deepest clinical takeaway from studying the Blueprint protocol is not whether Johnson is right or wrong to take these drugs. The takeaway is how large the evidence gaps remain for human longevity pharmacology.

Rapamycin has compelling mouse data and a mechanistic rationale that dates to a landmark 2009 Nature paper showing late-life treatment extended median lifespan in C57BL/6 mice by 28% in females and 38% in males [24]. Metformin has strong observational signals. GLP-1 agonists have cardiovascular outcome data in diabetic and obese populations. But no completed RCT has enrolled healthy middle-aged adults, randomized them to any of these drugs, and followed them long enough to measure lifespan or healthy-lifespan extension as a primary endpoint.

Johnson is, in effect, running an N=1 experiment in public. The value is transparency. The limitation is that N=1 cannot establish causation for longevity outcomes in a biological system with a 70-to-90-year time horizon.

Anyone considering a Blueprint-adjacent protocol should discuss baseline labs with their physician before adding any prescription compound. For rapamycin specifically, a starting dose of 5 mg weekly with lipid monitoring at 6 and 12 weeks is consistent with practices documented in published longevity clinic case series [25].